PD-L1 circulating tumor cells (CTCs) can be used as a predictive biomarker in patients with HCC who receive PD-1 inhibitors in combination with intensive radiation therapy (IMRT) and antiangiogenic therapy (32). Here, CD274 is linked to hepatocellular carcinoma.